A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
- 65 Downloads
The development of nucleoside analogues has had a major impact on cancer therapy. CS-682 is a novel, orally administered nucleoside analogue with a unique mechanism of action. CS-682 undergoes conversion to the active metabolite, CNDAC, which then leads to the inhibition of DNA polymerase and a novel “DNA self-strand breaking mechanism.” We conducted a Phase I study of CS-682, administered orally five days per week in patients with refractory solid tumor malignancies. Forty-eight patients were enrolled on study. The recommended phase II dose of 30 mg/m2 given orally once daily for 5 days a week for 4 weeks followed by 2 weeks off drug, was well tolerated. The most common dose limiting toxicity was neutropenia, which occurred at the highest dose levels of CS-682. This was correlated with higher CNDAC Cmax and AUC values. No tumor responses were noted in this heavily pretreated population. However, given the ease of administration and tolerability, further investigation of this agent is warranted.
KeywordsAntimetabolite CS-682 Phase I Pharmacokinetic
Unable to display preview. Download preview PDF.
- 3.Noble S, Goa K (1997) Gemcitabine: A review of its pharmacology and clinical potential in non-small cell lung cancer and pancreatic cancer. Drugs 54:447–472Google Scholar
- 4.Ruiz, van Haperen VW, Veerman G, Vermorken JB, Peters GJ (1993) 2′,2-difluoro-deoxycytidine (gemcitabine)incorporation into RNA and DNA of tumor cell lines. Biochem Pharmacol 46:762–766Google Scholar
- 5.Hanaoka K, Suzuki M, Kobayashi T, Tanzawa F, Tanaka K, Shibayama T, Miura S, Ikelda T, Iwabuchi H, Nakagawa A, Mitsuhashi Y, Hisaoka M, Kaneko M, Tomida A, Wataya Y, Nomura T, Sasaki T, Matsuda A, Tsuruo T, Kurakata S (1999) Antitumor activity and novel DNA self-strand breaking mechanism of CNDAC (1(2-c-cyano-2-deoxy-β-D-arabino-pentofuranosyl) cytosine) and its N4 –Palmitoyl Derivative (CS-682). Int J Cancer 82:226–236PubMedCrossRefGoogle Scholar